Frontiers in Medicine (Apr 2024)

Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitor

  • Seung-Yul Lee,
  • Seung-Yul Lee,
  • Jae Young Cho,
  • Diana A. Gorog,
  • Diana A. Gorog,
  • Dominick J. Angiolillo,
  • Kyeong Ho Yun,
  • Jong-Hwa Ahn,
  • Jin-Sin Koh,
  • Yongwhi Park,
  • Seok-Jae Hwang,
  • Jin-Yong Hwang,
  • Jin Won Kim,
  • Yangsoo Jang,
  • Young-Hoon Jeong

DOI
https://doi.org/10.3389/fmed.2024.1349577
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundIn patients undergoing percutaneous coronary intervention (PCI), the use of anti-inflammatory therapy with colchicine is associated with a reduction of recurrent ischemic events. The mechanisms of such findings are not fully elucidated.ObjectivesTo investigate the effects of colchicine versus aspirin on inflammation and platelet reactivity in patients with acute coronary syndrome (ACS) undergoing PCI.MethodsThis observational study compared laboratory measurements in ACS patients receiving single antiplatelet therapy with ticagrelor or prasugrel plus colchicine (MACT) (n = 185) versus conventional dual-antiplatelet therapy (DAPT) with aspirin plus ticagrelor or prasugrel (n = 497). The primary outcome was the frequency of high residual inflammation, defined as high-sensitivity C-reactive protein (hs-CRP) ≥2 mg/L at 1 month post-PCI. Multiple sensitivity analyses were performed for the primary outcome, including multivariable adjustment, propensity-score matching, and inverse-probability weighted methods.ResultsOne month after PCI, patients treated with MACT had significantly lower levels of hs-CRP compared to those treated with DAPT (0.6 [0.4–1.2] vs. 0.9 [0.6–2.3] mg/L, p < 0.001). The frequency of high residual inflammation was also lower in the MACT group (10.8% vs. 27.2%, p < 0.001) (odds ratio [95% confidence interval] = 0.33 [0.20–0.54], p < 0.001). This effect was consistent across sensitivity analyses. There was no difference in platelet reactivity between MACT and DAPT (49.6 ± 49.0 vs. 51.5 ± 66.4 P2Y12 reaction unit [PRU] measured by VerifyNow, p = 0.776).ConclusionIn ACS patients undergoing PCI, MACT was associated with a lower rate of high residual inflammation without increasing platelet reactivity compared to conventional DAPT.Clinical trial registrationNCT04949516 for MACT pilot trial and NCT04650529 for Gyeongsang National University Hospital registry.

Keywords